Insights from Mizuho Americas
-
Category: Research
Dry Eye on the Rise
There's been little improvement in treatment for dry eye disease over the past 20 years, but biotech analyst Difei Yang says new therapies are showing promise.
-
Category: Research
Equity Research Analyst Mara Goldstein on the Evolving Immuno-Oncology Sector
With scientific breakthroughs in genomics, antibody discovery, and cell and gene therapies, oncology is expected to attract a bigger R&D spend globally than ever before.
-
Category: Research
The History of Cancer Care
From hopeless to hyper-targeted, Salim Syed walks us through the evolution of cancer treatments— from early surgery in ancient times to the exciting prospects for immunotherapy, targeting tell-tale neoantigen proteins that identify cancer cells.
-
Category: Research
Time for a Checkup? Acute Care Booms with the Baby Boomers
The baby boomer generation is aging and it's impacting the healthcare market - acute care, in particular. Healthcare Services Analyst Ann Hynes helps us understand why.
-
Category: Research
Gene Therapy: Will it Unlock Miracle Cures? A Q&A with Analyst Difei Yang
Our therapeutic biotechnology analyst Difei Yang talks about exciting advances in gene therapy that piqued her recent desire to cover the field for investors.
-
Category: Research
Washington Gridlock: Good for Healthcare Stocks?
Mizuho's Senior Healthcare Services Equity Analyst finds a correlation between S&P 500 healthcare indices and Washington gridlock.
-
Category: Research
The State of Alzheimer’s: A Q&A with Salim Syed
In this Q&A, our Biotech Analyst Salim Syed shares his perspective on the state of Alzheimer’s, the results of a clinic trial for BAN2401, and the ups and downs of developing drugs to treat this degenerative disease.
-
Category: Research
The Healthcare Makeover: Is Evolution or Amazon the Catalyst?
For months, there has been speculation that Amazon is about to enter into the pharmacy business. Ann Hynes, Mizuho Healthcare Services Analyst, thinks differently.
-
Category: Research
UnitedHealth: Just Getting Started - Raising PT to $235
UNH Management says that growth is 'just getting started' in key segments and they're taking a 'fresh focus at costs to drive better product price points'.